Genetic polymorphisms of ABCC2 and CBR3 can influence the efficacy and toxicity of doxorubicin therapy in Egyptian patients with non-Hodgkin lymphoma
Polymorphisms in ABCC2 and CBR3 genes may contribute to individual variability in DOX-related toxicity and treatment response.
Authors
- Galal Magdy (ORCID: https://orcid.org/0000-0003-0543-5065)
- Noha M. El-Khodary (ORCID: https://orcid.org/0000-0003-3303-0399)
- Gamal A. El-Azab
- H. A. Elmekawy
- Fawzy Elbarbry (ORCID: https://orcid.org/0000-0002-5238-2712)
- Ahmed Ali
- Khaled Abdelkawy
- Emad Sadaka
Institutions
- Pacific University Oregon (US)
- Kafrelsheikh University (EG)
- Mansoura University (EG)
- Tanta University (EG)
- Pacific University (US)
Publication Details
- Journal
- Xenobiotica
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1080/00498254.2025.2508814
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00